TICKERNERD
Menu
LFWDLFWDHealthcare · Medical Devices

LFWD Stock Forecast: Lifeward Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$6.43
−1.08% on the day

The 2 Wall Street analysts covering Lifeward Ltd. hold a median 12-month price target of $20 — +211.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$18.4M
Ticker Nerd rank
24 / 100
Median analyst target
$20
Analysts covering
2
Revenue$6.6M+15.7% y/y
Operating income−$4.2M
Net income−$11.5M
Free cash flow−$6.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.9%
1M
−13.1%
YTD
−7.1%
1Y
−35.3%
From 52W high
−35.3%
From 52W low
+39.9%
$4.60
$9.94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LFWD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lifeward Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Accruals
64
Momentum
52
Growth
50
Volatility
30
Quality
30
Revisions
26
Value
19
Issuance
5

Size (88): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LFWD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LFWD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26LFWDHigh $30Median $20Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $20High $30

The green dot is the last close — the median target sits +211.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Mar 2026HC Wainwright & Co.MaintainsBuy$4.50 → $10
18 Nov 2025HC Wainwright & Co.MaintainsBuy—
11 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Mar 2025Lake StreetMaintainsBuy—
20 Feb 2025HC Wainwright & Co.ReiteratesBuy—
20 Feb 2025Lake StreetMaintainsBuy—
10 Feb 2025Laidlaw & Co.InitiatesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
16 May 2024HC Wainwright & Co.MaintainsBuy—
15 Apr 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
3 July 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
24 Feb 2023HC Wainwright & Co.ReiteratesBuy—
15 Nov 2022HC Wainwright & Co.MaintainsBuy—
10 Aug 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LFWD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LFWD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Lifeward Ltd. returned −35.3% against +16.2% for the S&P 500, dividends included.

LFWD vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26LFWDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LFWD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Lifeward Ltd. (LFWD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 80% of US stocks

Price / sales
0.8×

Cheaper than 72% of US stocks

Price / book
1.5×

Cheaper than 53% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
15.7%

Higher than 63% of US stocks

Earnings growth (YoY)
15.7%

Higher than 54% of US stocks

Gross margin
40.9%

Higher than 51% of US stocks

Operating margin
−62.7%

Higher than 16% of US stocks

Net margin
−141.3%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−225.6%

Higher than 6% of US stocks

Return on assets
−47.3%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lifeward Ltd. (LFWD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lifeward Ltd. has a market value of $18.4M and an enterprise value of $15.5M.

  • Revenue in the twelve months to 30 June 2026: $21.8M. The latest quarter grew 15.7% year on year.

  • Net income over the same four quarters: −$30.8M, a −141.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−16.82.

  • Free cash flow in the twelve months to 30 June 2026: −$17.1M.

  • Shares outstanding: 2.8M.

  • Trailing P/E: −0.4×; forward P/E: −7.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lifeward Ltd. employs 81 people — $269K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

LFWD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LFWDLifeward Ltd.$18.4M
24
IRIXIRIDEX Corp.$15.4M
81
PAVMPAVmed, Inc.$21.5M
17
HSCSHeartSciences, Inc.$14.6M
48
NSPRInspireMD, Inc.$22.5M
50
PMIPicard Medical, Inc.$22.6M
24
SINTSINTX Technologies, Inc.$13.4M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lifeward Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LFWD news & analysis

Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

GlobeNewsWire · 15 Sept 2026positive

A peer-reviewed, independent study of Lifeward's ReWalk exoskeleton reported significant improvements in daily activity performance, user satisfaction, and reduced pain compared with wheelchair use. The findings were published by GlobeNewsWire.

Why it matters — A landmark independent study demonstrating clinical and quality-of-life benefits could strengthen the evidence base supporting Lifeward's ReWalk product for LFWD stakeholders.

Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy

GlobeNewsWire · 8 Sept 2026positive

Lifeward Ltd. published an updated investor presentation that highlights its commercial growth strategy. The announcement originated from the company's offices in Hudson, Massachusetts, and Yokneam Illit, Israel.

Why it matters — A Lifeward watcher would care because the updated presentation outlines the company's commercial growth strategy, offering insight into its forward-looking direction.

Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer

GlobeNewsWire · 31 Aug 2026positive

Lifeward announced the appointment of Josh Hexter as Interim Chief Executive Officer and Rami Aviram as Chief Financial Officer. The company said the experienced leadership team will build on its established commercial platform and continue its strategy to support the next phase of growth.

Why it matters — The leadership appointments signal an intention to maintain strategic continuity at the executive level, which is relevant to Lifeward watchers following the company's commercial progress.

Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026positive

Lifeward (LFWD) reported a Q2 loss of $1.46 per share, narrower than the Zacks Consensus Estimate of a $1.49 loss and well below the $6.96 loss per share recorded a year earlier, though revenue missed estimates. The quarterly results compare favorably to both consensus and the prior-year period.

Why it matters — LFWD watchers would care because the narrower-than-expected loss signals improving financial performance even as the company fell short of revenue estimates.

Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth

GlobeNewsWire · 14 Aug 2026positive

Lifeward Ltd. reported strong second quarter 2026 financial results, citing revenue growth and improved operating performance as its capital-efficient distribution strategy gains traction.

Why it matters — The results signal that Lifeward's commercial execution and rehabilitation-platform expansion are strengthening its financial position and operational momentum.

FAQ

Frequently asked questions about LFWD stock

What is the LFWD stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lifeward Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LFWD stock a buy right now?

Of the 2 analysts covering Lifeward Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifeward Ltd. 24 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LFWD?

As at 8 Oct 2026, Lifeward Ltd. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will LFWD stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +211.0% from the last close, and Ticker Nerd's factor model ranks Lifeward Ltd. 24 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LFWD stock forecast for 2030?

No analyst covering Lifeward Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.

How has LFWD stock performed over the past year?

Lifeward Ltd. returned -35.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lifeward Ltd. do?

Lifeward Ltd. is a medical device company that develops and commercializes rehabilitation technologies designed to improve mobility and support recovery for people with physical and neurological conditions.

What is the latest news on LFWD?

The most recent item we track (GlobeNewsWire, 15 Sept 2026): "Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain". A peer-reviewed, independent study of Lifeward's ReWalk exoskeleton reported significant improvements in daily activity performance, user satisfaction, and reduced pain compared with wheelchair use. The findings were published by GlobeNewsWire.

Company

About Lifeward Ltd.

Lifeward Ltd. is a medical device company that develops and commercializes rehabilitation technologies designed to improve mobility and support recovery for people with physical and neurological conditions. Its portfolio includes wearable robotic exoskeletons and related systems used in clinical, home, and community settings. Key products include the ReWalk personal exoskeleton, the ReStore soft exo-suit, the AlterG Anti-Gravity System, and MyoCycle devices, which are used in physical rehabilitation, post-stroke recovery, and mobility training. The company also serves institutions and individual users through direct sales and third-party distribution channels. Lifeward Ltd. operates across markets in the United States, Europe, and the Asia-Pacific region, positioning itself within the broader medical technology and rehabilitation equipment sector.

CEO Mr. William Mark Grant · 81 employees · Israel · https://golifeward.com